References
- Naranjo CA, Busto U, Sellers EM, . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
- Mutinga M, Castells M, Horan R, . Successful desensitization to 6-mercaptopurine in a patient with Crohn's disease. Am J Gastroenterol 2000;95:1383–1384.
- Nagai S, Nannya Y, Hangaishi A, . The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia. Leuk Res 2009;33: 1427–1429.
- Lobel EZ, Korelitz BI, Vakher K, . Prolonged remission of severe Crohn's disease after fever and leukopenia caused by 6-mercaptopurine. Dig Dis Sci 2004;49:336–338.
- Andersen JM, Tiede JJ. Serum sickness associated with 6-mercaptopurine in a patient with Crohn's disease. Pharmacotherapy 1997;17:173–176.
- Rehr EL, Swanson KA, Kern JA. Mercaptopurine-induced fever in a patient with Crohn's disease. Ann Pharmacother 1992;26:907–909.
- Chen LJ, Nightingale G, Baer MR. Mercaptopurine-induced fever: hypersensitivity reaction in a patient with acute lymphoblastic leukemia. Pharmacotherapy 2010;30:113.
- Wan Rosalina WR, Teh LK, Mohamad N, . Polymorphism of ITPA 94C > A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J Clin Pharm Ther 2011 May 5. [Epub ahead of print]
- Shipkova M, Franz J, Abe M, . Association between adverse effects under azathioprine therapy and inosine triphosphate pyrophosphatase activity in patients with chronic inflammatory bowel disease. Ther Drug Monit 2011;33:321–328.
- Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphate deficiency. J Hum Genet 2002;47:620–622.
- Marsh S, King CR, Ahluwalia R, . Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet 2004;49:579–581.